期刊文献+

人血浆中阿戈美拉汀的浓度测定及其药动学研究 被引量:1

Concentration determination of agomelatine in human plasma and its pharmacokinetics study
下载PDF
导出
摘要 目的:建立LC-MS/MS法测定阿戈美拉汀在人血浆中的浓度,并测定其在健康志愿者体内的药动学参数。方法:以ACQUITY UPLC BEH C18柱(50mm×2.1mm,1.7μm)为分析柱,50mmol/L甲酸铵-甲酸-水(0.75∶1.25∶98)溶液(A)-乙腈(B)为流动相,梯度洗脱(0~0.65min,43%B相;0.65~0.66min,43%~90%B相;0.66~1.00min,90%B相;1.00~1.10min,90%~43%B相,1.10~2.50min,43%B相)。采用电喷雾离子源,多离子反应监测(MRM)正离子扫描分析。阿戈美拉汀和内标阿戈美拉汀-氘6离子对分别为m/z244.1→185.1和m/z250.1→188.1。测定48名健康志愿者单剂量口服阿戈美拉汀25mg后的血药浓度和药动学参数。结果:在0.05~10.00ng/ml浓度范围内,阿戈美拉汀具有良好的线性关系。日内、日间精密度RSD均<6%,平均提取回收率在77.28%~83.67%(n=6)。单次口服给药后,阿戈美拉汀的cmax为(16.16±31.52)ng/ml,AUC0~∞为(17.05±21.17)ng·h·ml^(-1),AUC0~12h为(16.95±21.11)ng·h·ml^(-1),tmax为(1.20±0.88)h,t1/2为(0.96±0.33)h。结论:本方法简便、灵敏、精确,重现性好,可用于人血浆中阿戈美拉汀浓度的测定及药动学研究。 Objective:To establish a LC-MS/MS method for concentration determination of agomelatine in human plasma and to determine its pharmacokinetics parameters in healthy volunteers.Methods:ACQUITY UPLC BEH C_(18)(50 mm×2.1 mm,1.7μm)was used with the mobile phase consisting of 50 mmol/L ammonium formate-formic acid-water(0.75∶1.25∶98,phase A)and acetonitrile(phase B)at a gradient elution(0-0.65 min 43% B,0.65-0.66 min 43%-90% B,0.66-1.00 min 90% B,1.00-1.10 min 90%-43% B,1.10-2.50 min 43% B).Mass spectrometry was performed using electro spray ionization(ESI),combined with positive ion scanning switch.The mass transition pairs of m/z244.1→185.1 and m/z250.1→188.1 were agomelatine and internal standard[~2H_6]-agomelatine.The plasma concentrations and pharmacokinetics parameters were determined after administration of a single oral dose of 25 mg agomelatine in 48 healthy volunteers.Results:In the concentration ranges of 0.05-10.00 ng/ml,agomelatine displayed good linearity.The intra-and inter-day precisions(RSD)were less than 6%.The average recovery rate was 77.28%-83.67%(n=6).The main pharmacokinetics parameters after a single oral dose of agomelatine were as follows:cmax(16.16±31.52)ng/ml,AUC_(0-∞)(17.05±21.17)ng·h·ml^(-1),AUC0-12 h(16.95±21.11)ng·h·ml^(-1),tmax(1.20±0.88)h,and t1/2(0.96±0.33)h.Conclusion:The established method was convenient,sensitive,accurate and reproducible,and it could be used for concentration determination of agomelatine in human plasma and the study of pharmacokinetics.
作者 程捷 贺娟 茅晓寅 周沁逸 张梦琪 张慧 CHENG Jie;HE Juan;MAO XiaoYin;ZHOU QinYi;ZHANG MengQi;ZHANG Hui(Institution for Drug Clinical Trials,Shanghai Xuhui Central Hospital,Shanghai 200031,China;Department of Pharmacy,Community Health Service Center of Xietu Street,Xuhui District of Shanghai,Shanghai 200032,China)
出处 《药学服务与研究》 CAS 2018年第3期199-202,共4页 Pharmaceutical Care and Research
关键词 阿戈美拉汀 血药浓度 药代动力学 色谱法 高效液相 质谱法 联用 agomelatine blood concentration pharmacokinetics chromatography high performance liquid massspeetrometry tandem
  • 相关文献

参考文献1

二级参考文献10

  • 1Wang X, Ma HM, Zhou YS. The graphical synthetic routes of agomelatine [ J ].中国药物化学杂志,2012,99(4):334-336.
  • 2Landoh HP, Wehrle R. Antagonism of serotonergic 5-HT2A/2C receptors : mutual improvement of sleep, cognition and mood [ J ]. Eur J Neurosci ,2009 ,29 (9) : 1 795 - 1 809.
  • 3Howland RH. Critical appraisal and update on the clinical utility of agomelatine, a melatonergic agonist, for the treatment of major depressive disease in adults[ J]. Neuropsychiatr Dis Treat,2009, 5:563 - 576.
  • 4Millan M, Gobert A, Lejeune F,et al. The novel melatonin agonist agomelatine ($20098) is an antagonist at 5-hydroxyt13,ptamine 2C receptors,blockade of which enhances the activity of fronto- cortical dopaminergic and adrenergic pathways [ J ]. J Pharmacol Exp Ther ,2003 ,306( 3 ) :954 -964.
  • 5Banasr M, Soumier A, Hery M, et al. Agomelatine, a new antide- pressant,induces regional changes in hippocampal neurogenesis [ J ]. Biol Psychiatry,2006,59 ( 11 ) : 1 087 - 1 096.
  • 6Wei MJ, Zhang ZF, Zhang ZF. Discussion on accuracy in the analysis of biological samples and improvement measures [ EB/ OL]. (2012-04-11) [ 2012-09-30]. http ://www. cde. org. cn/ dzkw. do? method = largePage&id =312642.
  • 7European Medicines Agency. CHMP ASSESSMENT REPORT FOR Valdoxan [ EB/OL]. ( 2008-11-20 ) [ 2011-12-121. http :// www. ema. europa, eu/docs/en_GB/document library/EPAR_-_ Public_assessment_report/human/OOO915 /WC500046226. pdf.
  • 8European Medicines Agency. Guideline on the investigation of bioequivalence[ EB/OLI. (20104)1-20 ) [ 2011-12-121. http :// www. ema. europa, eu/docs/en_GB/document_library/Scientific _guideline/2010/O1/WC500070039. pdf.
  • 9Chow SC, Liu J. Design and Analysis of Bioavailability and Bio- equivalence Studies[ M]. CRC Press,2000.
  • 10Patil SR, Nerurkar KK, Kalamkar AM, et al. Validated LC-MS/ MS method for quantification of agomelatine in human plasma and its application in a pharmacokinetic study [ J ]. J Mass Spectrom, 2012,47 ( 1 ) :23 - 28.

共引文献1

同被引文献17

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部